Why do boarders talk of listing price/Kostak etc? First of all they aren''t sure of any allotment as it will be decided by lottery. Then again one is getting 60 shares at best. Either you keep it for long time or flip it for some listing gains. What is gained by asking for GMP, etc beats simple logic. After you have applied, the only thing you can do is wait for allotment pattern, and if lucky to have been allotted shares, wait for listing day. Or wait out for the next IPO and take your chance....
Does this lottery concept applied for HNI category also? Does this lottery, irrespective of bidding value? or only people who bid cut off price entitled for this lucky draw? I had bid @ 241 under HNI category, is there any chance for me to part of this lucky draw?
SINCE new RETAIL allotments system are based on application recieved.and not the quantity applied for ,All will be allotted 60 shares irrespective of quantity applied 15k or 2 lacs. As the Application recieved may be 3 lac to 4 lac , 60 shares will be allotted by lottery .
The initial public offer (IPO) of Syngene International received bids for a total of 50.69 crore shares on the last day of bidding for the IPO today, 29 July 2015, compared with up to 1.6 crore equity shares on offer, as per data from the National Stock Exchange (NSE) website. The IPO was subscribed 31.68 times. The price band for the IPO was fixed at Rs 240 to Rs 250 per share. The company has finalized allocation of 60 lakh shares to a total of 13 anchor investors at the top end of the price band.
Promoter Biocon is selling shares through the IPO and hence Syngene International will not get any funds from the IPO. Biocon is selling a total of 2.2 crore shares of Syngene International via the IPO. Post offer, Biocon will hold 74.5%.
Syngene International has raised Rs 150 crore from sale of shares to 13 anchor investors. The company had on Friday, 24 July 2015, finalized allocation of 60 lakh shares to a total of 13 anchor investors at Rs 250 per share which is the top end of the Rs 240-250 price band for the IPO. The company will issue 8 lakh shares each to Reliance Pharma Fund and BNP Paribas Arbitrage Fund. Government of Singapore will be allotted 6.59 lakh shares and the Monetary Authority of Singapore will be allotted 3.4 lakh shares. Blackrock India Equity Fund will be allotted 6 lakh shares. Goldman Sachs India Fund, ICICI Prudential Top 100 Fund, Tata Equity Opportunities Fund, Columbia Emerging Markets Fund and DB International (Asia) will be allotted 4 lakh shares each.
Biocon will the proceeds to meet its capital expenditure requirements and to fund the ongoing research of its new biosimilar product portfolio that comprises several late-stage projects that need investment for global clinical trials.
For the three fiscal years ended 31 March 2015 (FY 2015), Syngene International''s total revenue, net profit and EBITDA grew at a CAGR of 27.7%, 35.1% and 28.3%, respectively. The company registered a net profit of Rs 175 crore on total revenue of Rs 871.60 crore for FY 2015.
Promoted by Biocon, Syngene International is a leading India-based contract research organization (CRO) offering a suite of integrated and end-to-end discovery and development services for novel molecular entities (NMEs) across industrial sectors.